Multiple Biologics Treatment Failures in Patients with Psoriasis: A Case Series of 4 Patients

Authors

  • Mikkel Bak Jensen Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark https://orcid.org/0000-0003-2442-5735
  • Nikolai Loft Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark https://orcid.org/0000-0002-2950-3280
  • Claus Zachariae Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark https://orcid.org/0000-0001-5506-1319
  • Lone Skov Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark https://orcid.org/0000-0002-4784-9680

DOI:

https://doi.org/10.2340/actadv.v105.42987

Keywords:

Psoriasis, Biologics, JAK inhibitors, Biomarkers, Therapy

Downloads

Download data is not yet available.

References

Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369: m1590.

https://doi.org/10.1136/bmj.m1590 DOI: https://doi.org/10.1136/bmj.m1590

Loft N, Egeberg A, Rasmussen MK, et al. Prevalence and characterization of treatment‐refractory psoriasis and super‐responders to biologic treatment: a nationwide study. J Eur Acad Dermatol Venereol 2022; 36: 1284-1291.

https://doi.org/10.1111/jdv.18126 DOI: https://doi.org/10.1111/jdv.18126

Mason KJ, Alabas OA, Dand N, et al. Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case-control study. Br J Dermatol 2024; 190: 441-444.

https://doi.org/10.1093/bjd/ljad446 DOI: https://doi.org/10.1093/bjd/ljad446

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ. A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis. Br J Dermatol 2018; 178: 86-94.

https://doi.org/10.1111/bjd.15753 DOI: https://doi.org/10.1111/bjd.15753

Hjort G, Schwarz CW, Skov L, Loft N. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis. JAMA Dermatol 2024; 160: 830-837.

https://doi.org/10.1001/jamadermatol.2024.1677 DOI: https://doi.org/10.1001/jamadermatol.2024.1677

Schwarz CW, Loft N, Rasmussen MK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol 2021; 101: adv00579.

https://doi.org/10.2340/actadv.v101.351 DOI: https://doi.org/10.2340/actadv.v101.351

Bokor-Billmann T, Schäkel K. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatolog Treat 2019; 30: 216-220.

https://doi.org/10.1080/09546634.2018.1506081 DOI: https://doi.org/10.1080/09546634.2018.1506081

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol 2020; 183: 294-302.

https://doi.org/10.1111/bjd.18981 DOI: https://doi.org/10.1111/bjd.18981

Downloads

Additional Files

Published

2025-03-09

How to Cite

Jensen, M. B., Loft, N., Zachariae, C., & Skov, L. (2025). Multiple Biologics Treatment Failures in Patients with Psoriasis: A Case Series of 4 Patients. Acta Dermato-Venereologica, 105, adv42987. https://doi.org/10.2340/actadv.v105.42987

Issue

Vol. 105 (2025)

Section

Research letter

Categories

License

Copyright (c) 2025 Mikkel Bak Jensen, Nikolai Loft, Claus Zachariae, Lone Skov

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC